The Medical Letter on Drugs and Therapeutics
- A Three-Antigen Hepatitis B Vaccine (PreHevbrio)
- Tretinoin/Benzoyl Peroxide Cream (Twyneo) for Acne
- Delayed-Release Budesonide (Tarpeyo) for Primary Immunoglobulin A Nephropathy
- In Brief: OTC Alcaftadine (Lastacaft Once Daily Relief) for Allergic Conjunctivitis
- In Brief: Higher-Dose Semaglutide (Ozempic) for Type 2 Diabetes
- Addendum: Dexlansoprazole for GERD
A Three-Antigen Hepatitis B Vaccine (PreHevbrio)
May 16, 2022 (Issue: 1650)The FDA has licensed PreHevbrio (VBI Vaccines), a recombinant, 3-antigen, 3-dose hepatitis B vaccine, for the prevention of infection caused by all known subtypes of hepatitis B virus (HBV) in adults. It has been available in Israel since...more
- MK Weng et al. Universal hepatitis B vaccination in adults aged 19-59 years: updated recommendations of the Advisory Committee on Immunization Practices – United States, 2022. MMWR Morb Mortal Wkly Rep 2022; 71:477.
- A two-dose hepatitis B vaccine for adults (Heplisav B). Med Lett Drugs Ther 2018; 60:17.
- T Vesikari et al. Immunogenicity and safety of a tri-antigenic versus a mono-antigenic hepatitis B vaccine in adults (PROTECT): a randomised, double-blind, phase 3 trial. Lancet Infect Dis 2021; 21:1271.
- T Vesikari et al. Immunogenicity and safety of a 3-antigen hepatitis B vaccine vs a single-antigen hepatitis B vaccine: a phase 3 randomized clinical trial. JAMA Netw Open 2021; 4:e2128652.
- D Shouval et al. Enhanced immune response to hepatitis B vaccination through immunization with a Pre-S1/Pre-S2/S vaccine. Med Microbiol Immunol 2015; 204:57.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.